EMD-25649

Helical reconstruction
18.0 Å
EMD-25649 Deposition: 06/12/2021
Map released: 28/12/2022
Last modified: 17/01/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-25649

Helical Reconstruction of the C-terminal Half of Leucine Rich Repeat Kinase 2 (LRRK2) (I2020T) bound to 11-protofilament microtubule in presence of MLi-2 kinase inhibitor

EMD-25649

Helical reconstruction
18.0 Å
EMD-25649 Deposition: 06/12/2021
Map released: 28/12/2022
Last modified: 17/01/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Bos taurus, Homo sapiens
Sample: LRRK2RCKW filament bound to a 11-pf microtubule with MLi-2 present
Raw data: EMPIAR-10925

Deposition Authors: Matyszewski M , Leschziner AE
Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
Snead DM, Matyszewski M , Dickey AM , Lin YX, Leschziner AE , Reck-Peterson SL
(2022) Nat Struct Mol Biol , 29 , 1196 - 1207
PUBMED: 36510024
DOI: doi:10.1038/s41594-022-00863-y
ISSN: 1545-9985
Abstract:
Leucine-rich repeat kinase 2 (LRRK2) is one of the most commonly mutated genes in familial Parkinson's disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-EM structure of the catalytic half of LRRK2, containing its kinase, in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2 but is not linked to PD. Although LRRK1's structure is similar to that of LRRK2, we find that LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2's GTPase that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2's kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.